TrialPharmacoEconomics2021

The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.

Fredrik O L Nilsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.